Edging closer to PET monitoring of therapy response in Hodgkin lymphoma

July 11, 2013

Personalized therapy assessment for Hodgkin lymphoma (HL) with interim FDG PET could help step up or step down treatment to find the curative sweet spot, but the transition from PET-adaptive clinical trials to practice requires additional time to prove broad benefit for patients, according to a review published July 1 in the Journal of Nuclear Medicine.

Lale Kostakoglu, MD, from the department of radiology division of nuclear medicine at Mount Sinai Medical Center in New York City, and colleagues collected literature on interim PET research and clinical trials using adaptive PET in the assessment of patients with HL to evaluate its effectiveness for tailoring treatments to each patient’s level of risk and response to therapy.